Evogene Net Worth
Evogene Net Worth Breakdown | EVGN |
Evogene Net Worth Analysis
Evogene's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Evogene's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Evogene's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Evogene's net worth analysis. One common approach is to calculate Evogene's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Evogene's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Evogene's net worth. This approach calculates the present value of Evogene's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Evogene's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Evogene's net worth. This involves comparing Evogene's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Evogene's net worth relative to its peers.
Enterprise Value |
|
To determine if Evogene is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evogene's net worth research are outlined below:
| Evogene generated a negative expected return over the last 90 days | |
| Evogene has high historical volatility and very poor performance | |
| Evogene may become a speculative penny stock | |
| Evogene has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.64 M. Net Loss for the year was (25.95 M) with profit before overhead, payroll, taxes, and interest of 766 K. | |
| Evogene currently holds about 35.25 M in cash with (21.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Evogene has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Evogene Q3 2024 Earnings Preview |
Evogene uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evogene. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evogene's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 16th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Evogene's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evogene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evogene backward and forwards among themselves. Evogene's institutional investor refers to the entity that pools money to purchase Evogene's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Investment Group, Llc | 2024-09-30 | 10 K | Pnc Financial Services Group Inc | 2024-09-30 | 3.8 K | Group One Trading, Lp | 2024-06-30 | 0.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 0.0 | Commonwealth Equity Services Inc | 2024-06-30 | 0.0 | Malaga Cove Capital, Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 |
Follow Evogene's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.2 M.Market Cap |
|
Project Evogene's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (1.98) | (1.88) |
When accessing Evogene's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Evogene's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evogene's profitability and make more informed investment decisions.
Evaluate Evogene's management efficiency
Evogene has return on total asset (ROA) of (0.2846) % which means that it has lost $0.2846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8237) %, meaning that it created substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.66. In addition to that, Return On Capital Employed is likely to drop to -0.63. At this time, Evogene's Total Assets are very stable compared to the past year. As of the 21st of November 2024, Non Currrent Assets Other is likely to grow to about 28.4 K, while Other Assets are likely to drop 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.25 | 5.31 | |
| Tangible Book Value Per Share | 4.37 | 4.22 | |
| Enterprise Value Over EBITDA | (1.32) | (1.38) | |
| Price Book Value Ratio | 3.30 | 3.14 | |
| Enterprise Value Multiple | (1.32) | (1.38) | |
| Price Fair Value | 3.30 | 3.14 | |
| Enterprise Value | 35.1 M | 33.3 M |
At Evogene, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 0.4902 | Revenue 9.4 M | Quarterly Revenue Growth 0.398 | Revenue Per Share 1.881 | Return On Equity (0.82) |
Evogene Earnings per Share Projection vs Actual
Evogene Corporate Management
| Rachel Gerber | Head Relations | Profile | |
| Amit res | Chief Ltd | Profile | |
| Dotan Borenstein | Chief Ltd | Profile | |
| Yaron Eldad | Chief Officer | Profile | |
| Eyal Ronen | Executive Development | Profile | |
| Nir Arbel | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.84) | Revenue Per Share 1.881 | Quarterly Revenue Growth 0.398 | Return On Assets (0.28) | Return On Equity (0.82) |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.